- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Clopidogrel resistance associated with gene polymorphism tied to adverse clinical outcomes following PCI: Study
New Delhi: Recent studies have reported a concerning issue in managing Acute Coronary Syndrome (ACS)-clopidogrel resistance. This phenomenon, where patients exhibit a reduced response to the antiplatelet medication clopidogrel, poses significant challenges to optimal patient care and clinical outcomes.
A recent study published in the Indian Heart Journal has emphasized the association between gene polymorphisms, clopidogrel resistance, and negative clinical outcomes after percutaneous coronary intervention (PCI).
Clopidogrel is a cornerstone in ACS treatment, helping to prevent thrombotic events by inhibiting platelet aggregation. CYP2C19 is a highly polymorphic enzyme that leads to varied responses to clopidogrel in ACS patients. Variants that result in loss of function (LOF) are linked to decreased efficacy or a complete lack of activity for clopidogrel. The relationship between LOF variants and reduced platelet inhibition has significant clinical implications. Factors such as patient demographics, genetic variations, and drug interactions are essential for understanding individual responses to clopidogrel.
In India, the prevalence of clopidogrel resistance ranges from 5% to 44%. Ischemic and bleeding events risk can be significantly minimized by tailoring antiplatelet therapy based on platelet function testing (PFT), genetic profiles, and clinical characteristics, the researchers noted.
Against the above background, Heemanshu Lodhi, Department of Cardiology, Army Hospital Research and Referral, Delhi Cantonment, New Delhi, and colleagues aimed to assess the association between CYP2C19 metabolization status and clopidogrel resistance by PFT based on platelet reactivity units (PRUs).
The study included 668 individuals undergoing PCI, approved by the Institutional Review Board (IRB) with informed consent. Samples were collected per ICMR and AHRR guidelines, focusing on patients with acute coronary syndrome based on criteria from previous studies. Eligible participants were those willing to undergo follow-up assessments. DNA was isolated using the QIAGEN DNA Mini Kit, and platelet function was evaluated using the Verify PRU test according to the manufacturer’s protocol.
The key findings of the study were as follows:
- 54.64% of the patients who carried the LOF variants were categorized as poor metabolizers for clopidogrel, while the rest individuals belong to ultra (18.26%) and extensive (27.1%) metabolizers.
- To examine the association between genetic testing results related to clopidogrel metabolization status and PRU values, platelet function testing (PFT) was randomly conducted for 143 individuals, of whom 45%, 12%, and 43% exhibited good, intermediate, and poor drug effects, respectively.
- There was a significant statistical correlation between genetic test results and PRU values with an Odds ratio (OR) of 10.4.
- In TVR and TLR cases, 75% and 88.85% were clopidogrel resistant (Intermediate Metabolizers and Poor Metabolizers) respectively.
- 88.80% of the individuals had PRU values above 160, indicating increased platelet reactivity in TLR individuals.
- Among patients with ISR, 80% had PRU values above 160, and 80% were clopidogrel resistant.
- All individuals with stent thrombosis were clopidogrel resistant, and 100% had PRU values above 160.
- Twelve patients died due to cardiovascular disease, 75% were clopidogrel resistant, and 83.32% had more than 160 PRU values.
"The study demonstrates the association between CYP2C19 LOF polymorphisms and adverse clinical outcomes in ACS patients following PCI. This emphasizes the need for personalized treatment approaches based on genetic findings to optimize antiplatelet therapy and enhance patient outcomes," the researchers concluded.
Reference:
Lodhi, H., Bhat, K. G., Guleria, V. S., Pillai, R. K. J., Goel, R., Sharma, N., Sharma, A., & Sharma, V. (2024). Clopidogrel Resistance and its effect on clinical outcomes in Acute Coronary Syndrome. Indian Heart Journal. https://doi.org/10.1016/j.ihj.2024.07.003
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751